These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Activity of protegrins against yeast-phase Candida albicans. Cho Y; Turner JS; Dinh NN; Lehrer RI Infect Immun; 1998 Jun; 66(6):2486-93. PubMed ID: 9596706 [TBL] [Abstract][Full Text] [Related]
8. Modulation of Neisseria gonorrhoeae susceptibility to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division efflux pump family. Shafer WM; Qu X; Waring AJ; Lehrer RI Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1829-33. PubMed ID: 9465102 [TBL] [Abstract][Full Text] [Related]
9. Synthesis of protegrin-related peptides and their antibacterial and anti-human immunodeficiency virus activity. Tamamura H; Murakami T; Horiuchi S; Sugihara K; Otaka A; Takada W; Ibuka T; Waki M; Yamamoto N; Fujii N Chem Pharm Bull (Tokyo); 1995 May; 43(5):853-8. PubMed ID: 7553971 [TBL] [Abstract][Full Text] [Related]
10. Antimicrobial susceptibilities of strains of Neisseria gonorrhoeae in Bangkok, Thailand: 1994-1995. Knapp JS; Wongba C; Limpakarnjanarat K; Young NL; Parekh MC; Neal SW; Buatiang A; Chitwarakorn A; Mastro TD Sex Transm Dis; 1997 Mar; 24(3):142-8. PubMed ID: 9132980 [TBL] [Abstract][Full Text] [Related]
11. Change in membrane permeability induced by protegrin 1: implication of disulphide bridges for pore formation. Mangoni ME; Aumelas A; Charnet P; Roumestand C; Chiche L; Despaux E; Grassy G; Calas B; Chavanieu A FEBS Lett; 1996 Mar; 383(1-2):93-8. PubMed ID: 8612801 [TBL] [Abstract][Full Text] [Related]
13. Development of protegrins for the treatment and prevention of oral mucositis: structure-activity relationships of synthetic protegrin analogues. Chen J; Falla TJ; Liu H; Hurst MA; Fujii CA; Mosca DA; Embree JR; Loury DJ; Radel PA; Cheng Chang C; Gu L; Fiddes JC Biopolymers; 2000; 55(1):88-98. PubMed ID: 10931444 [TBL] [Abstract][Full Text] [Related]
14. Susceptibility of Neisseria gonorrhoeae to antimicrobial peptides from amphibian skin, dermaseptin, and derivatives. Zairi A; Tangy F; Ducos-Galand M; Alonso JM; Hani K Diagn Microbiol Infect Dis; 2007 Mar; 57(3):319-24. PubMed ID: 17254733 [TBL] [Abstract][Full Text] [Related]
15. Analysis of mutations within multiple genes associated with resistance in a clinical isolate of Neisseria gonorrhoeae with reduced ceftriaxone susceptibility that shows a multidrug-resistant phenotype. Tanaka M; Nakayama H; Huruya K; Konomi I; Irie S; Kanayama A; Saika T; Kobayashi I Int J Antimicrob Agents; 2006 Jan; 27(1):20-6. PubMed ID: 16318912 [TBL] [Abstract][Full Text] [Related]
16. Potent and rapid antigonococcal activity of the venom peptide BmKn2 and its derivatives against different Maldi biotype of multidrug-resistant Neisseria gonorrhoeae. Arpornsuwan T; Buasakul B; Jaresitthikunchai J; Roytrakul S Peptides; 2014 Mar; 53():315-20. PubMed ID: 24184420 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and solution structure of the antimicrobial peptide protegrin-1. Aumelas A; Mangoni M; Roumestand C; Chiche L; Despaux E; Grassy G; Calas B; Chavanieu A Eur J Biochem; 1996 May; 237(3):575-83. PubMed ID: 8647100 [TBL] [Abstract][Full Text] [Related]
19. Phosphoethanolamine substitution of lipid A and resistance of Neisseria gonorrhoeae to cationic antimicrobial peptides and complement-mediated killing by normal human serum. Lewis LA; Choudhury B; Balthazar JT; Martin LE; Ram S; Rice PA; Stephens DS; Carlson R; Shafer WM Infect Immun; 2009 Mar; 77(3):1112-20. PubMed ID: 19114544 [TBL] [Abstract][Full Text] [Related]
20. A spontaneous mutant of Neisseria gonorrhoeae with decreased resistance to neutrophil granule proteins. Shafer WM; Onunka V; Hitchcock PJ J Infect Dis; 1986 May; 153(5):910-7. PubMed ID: 3084666 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]